Analyzing Vicapsys Life Sciences (OTCMKTS:VICP) and InflaRx (NASDAQ:IFRX)

Vicapsys Life Sciences (OTCMKTS:VICPGet Free Report) and InflaRx (NASDAQ:IFRXGet Free Report) are both small-cap construction companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, risk and dividends.

Valuation & Earnings

This table compares Vicapsys Life Sciences and InflaRx”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vicapsys Life Sciences N/A N/A -$1.18 million ($0.03) -50.33
InflaRx $70,000.00 1,329.01 -$46.18 million ($0.89) -1.78

Vicapsys Life Sciences has higher earnings, but lower revenue than InflaRx. Vicapsys Life Sciences is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vicapsys Life Sciences and InflaRx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vicapsys Life Sciences N/A N/A N/A
InflaRx -44,046.09% -47.03% -41.56%

Risk & Volatility

Vicapsys Life Sciences has a beta of -4.14, meaning that its stock price is 514% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Vicapsys Life Sciences and InflaRx, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vicapsys Life Sciences 0 0 0 0 N/A
InflaRx 0 0 1 0 3.00

InflaRx has a consensus price target of $8.00, indicating a potential upside of 406.33%. Given InflaRx’s higher probable upside, analysts clearly believe InflaRx is more favorable than Vicapsys Life Sciences.

Insider & Institutional Ownership

42.4% of InflaRx shares are held by institutional investors. 6.0% of Vicapsys Life Sciences shares are held by insiders. Comparatively, 16.3% of InflaRx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

InflaRx beats Vicapsys Life Sciences on 7 of the 12 factors compared between the two stocks.

About Vicapsys Life Sciences

(Get Free Report)

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.

About InflaRx

(Get Free Report)

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Receive News & Ratings for Vicapsys Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicapsys Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.